( NASDAQ-NMS:ENMD )

News from entremed, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 13, 2014, 07:00 ET EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other...


Jun 03, 2014, 07:00 ET EntreMed appoints Franklin C. Salisbury, Jr., President of NFCR, to Board of Directors

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other...


May 19, 2014, 07:00 ET EntreMed Announces Poster Presentations At ASCO On ENMD-2076

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases,...


May 15, 2014, 07:00 ET EntreMed Reports First Quarter 2014 Financial Results

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases,...


Mar 21, 2014, 07:00 ET EntreMed Reports 2013 Fourth Quarter And Full Year Financial Results

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases,...


Jan 13, 2014, 07:00 ET EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of diseases, announced today...


Nov 14, 2013, 07:00 ET EntreMed Reports Third Quarter 2013 Financial Results

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...


Oct 31, 2013, 07:00 ET EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...


Oct 22, 2013, 13:00 ET Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatocellular Carcinoma

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...


Oct 21, 2013, 07:00 ET Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer

 EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...


Aug 14, 2013, 07:00 ET EntreMed Reports Second Quarter 2013 Financial Results

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...


Jul 29, 2013, 07:00 ET EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials

EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...


Jun 27, 2013, 07:00 ET EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA To Expand Clinical Trial For Advanced/Metastatic Sarcoma

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...


May 15, 2013, 07:00 ET EntreMed Reports First Quarter 2013 Financial Results

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31,...


May 06, 2013, 07:00 ET Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...


May 03, 2013, 07:00 ET Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid Diseases

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...


Apr 05, 2013, 07:00 ET EntreMed Announces Changes to Board of Directors and CEO Appointment

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today...


Mar 21, 2013, 07:00 ET EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results...


Mar 01, 2013, 08:30 ET EntreMed To Raise $10.7 Million In Registered Direct Offering

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today...


Jan 23, 2013, 07:00 ET EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company, announced today the initiation of a single-center Phase 2 study entitled...


Jan 07, 2013, 07:00 ET EntreMed Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA To Advance Global Development Strategy

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today...


Jan 04, 2013, 07:00 ET EntreMed Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company, announced today the initiation of a second site for its Phase 2 study...


Dec 04, 2012, 13:00 ET PNAS Publishes Preclinical Results of EntreMed's 2ME2 for Multiple Sclerosis

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that...


Nov 26, 2012, 07:00 ET EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of...


Nov 14, 2012, 07:00 ET EntreMed Reports Third Quarter 2012 Financial Results

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported...